Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.

Brosch JR, Farlow MR, Risacher SL, Apostolova LG.

Neurotherapeutics. 2016 Nov 21. [Epub ahead of print] Review.

PMID:
27873182
2.

Oxaloacetate and adipose stromal cells-conditional medium synergistically protected potassium/serum deprivation-induced neuronal apoptosis.

Liu Q, Zhao G, Zhou C, Farlow MR, Du Y, Xu G, Gu H.

Brain Res Bull. 2016 Nov 2;128:7-12. doi: 10.1016/j.brainresbull.2016.11.002. [Epub ahead of print]

PMID:
27816553
3.

Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).

Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, Fagan AM, Goate A, Marcus DS, Xiong C, Allegri RF, Chhatwal JP, Danek A, Farlow MR, Fox NC, Ghetti B, Graff-Radford NR, Laske C, Martins RN, Masters CL, Mayeux RP, Ringman JM, Rossor MN, Salloway SP, Schofield PR, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network (DIAN)..

Lancet Neurol. 2016 Dec;15(13):1317-1325. doi: 10.1016/S1474-4422(16)30229-0.

PMID:
27777020
4.

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.

Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network..

Alzheimers Dement. 2016 Aug 29. pii: S1552-5260(16)30048-6. doi: 10.1016/j.jalz.2016.07.005. [Epub ahead of print]

PMID:
27583651
5.

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.

Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network..

Brain. 2016 Oct;139(Pt 10):2766-2777.

PMID:
27521573
6.

GDNF secreted from adipose-derived stem cells stimulates VEGF-independent angiogenesis.

Zhong Z, Gu H, Peng J, Wang W, Johnstone BH, March KL, Farlow MR, Du Y.

Oncotarget. 2016 Jun 14;7(24):36829-36841. doi: 10.18632/oncotarget.9208.

7.

Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults.

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative..

JAMA Neurol. 2016 Jun 1;73(6):721-32. doi: 10.1001/jamaneurol.2016.0580.

PMID:
27088965
8.

Corrigendum: Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis.

Fontanilla CV, Gu H, Liu Q, Zhu TZ, Zhou C, Johnstone BH, March KL, Pascuzzi RM, Farlow MR, Du Y.

Sci Rep. 2016 Apr 15;6:20747. doi: 10.1038/srep20747. No abstract available.

9.

[(11)C]PiB PET in Gerstmann-Sträussler-Scheinker disease.

Deters KD, Risacher SL, Yoder KK, Oblak AL, Unverzagt FW, Murrell JR, Epperson F, Tallman EF, Quaid KA, Farlow MR, Saykin AJ, Ghetti B.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):84-93.

10.

The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests.

Rattanabannakit C, Risacher SL, Gao S, Lane KA, Brown SA, McDonald BC, Unverzagt FW, Apostolova LG, Saykin AJ, Farlow MR.

J Alzheimers Dis. 2016;51(4):1145-55. doi: 10.3233/JAD-150729.

PMID:
26923008
11.

Adipose-derived Stem Cell Conditioned Media Extends Survival time of a mouse model of Amyotrophic Lateral Sclerosis.

Fontanilla CV, Gu H, Liu Q, Zhu TZ, Zhou C, Johnstone BH, March KL, Pascuzzi RM, Farlow MR, Du Y.

Sci Rep. 2015 Nov 20;5:16953. doi: 10.1038/srep16953. Erratum in: Sci Rep. 2016;6:20747.

12.

Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial.

Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC, Farlow MR.

Neurology. 2015 Dec 1;85(22):1937-44. doi: 10.1212/WNL.0000000000002171.

13.

Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease.

Farlow MR, Borson S, Connor SR, Grossberg GT, Mittelman MS.

Am J Alzheimers Dis Other Demen. 2016 Mar;31(2):156-62. doi: 10.1177/1533317515603501.

PMID:
26385946
14.

GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.

Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen PS, Petersen RC, Jack CR Jr, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI)..

Brain. 2015 Oct;138(Pt 10):3076-88. doi: 10.1093/brain/awv231.

15.

Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease.

Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Förster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ; Dominantly Inherited Alzheimer Network..

Neurology. 2015 Sep 1;85(9):790-8. doi: 10.1212/WNL.0000000000001903.

16.

An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

Lucey BP, Gonzales C, Das U, Li J, Siemers ER, Slemmon JR, Bateman RJ, Huang Y, Fox GB, Claassen JA, Slats D, Verbeek MM, Tong G, Soares H, Savage MJ, Kennedy M, Forman M, Sjögren M, Margolin R, Chen X, Farlow MR, Dean RA, Waring JF.

Alzheimers Res Ther. 2015 Jul 29;7(1):53. doi: 10.1186/s13195-015-0136-z.

17.

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NC, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JP, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW.

Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.

18.

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.

Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, Caputo A, Winblad B, Graf A.

Alzheimers Res Ther. 2015 Apr 27;7(1):23. doi: 10.1186/s13195-015-0108-3.

19.

Comprehensive gene- and pathway-based analysis of depressive symptoms in older adults.

Nho K, Ramanan VK, Horgusluoglu E, Kim S, Inlow MH, Risacher SL, McDonald BC, Farlow MR, Foroud TM, Gao S, Callahan CM, Hendrie HC, Niculescu AB, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI)..

J Alzheimers Dis. 2015;45(4):1197-206. doi: 10.3233/JAD-148009.

20.

Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.

Farlow MR, Sadowsky CH, Velting DM, Meng X, Islam MZ.

CNS Neurosci Ther. 2015 Jun;21(6):513-9. doi: 10.1111/cns.12385.

PMID:
25675992
Items per page

Supplemental Content

Loading ...
Support Center